SUNNYVALE, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- With pharmaceutical companies like Pfizer Inc. investing in shifting operations to a few bioscience hotspots (Wall Street Journal, November 23, 2011), Sunnyvale, CA, in the heart of Silicon Valley, is betting that a testimonial by successful CEO Rene Schena of Arrayit Corporation will seal the deal. Sunnyvale is currently home to Cepheid, Lockheed Martin, Yahoo, Network Appliance, Molecular Devices, Intuitive Surgical, St. Jude Medical, and research organizations such as the Parkinson's Institute and NASA Ames Space Science Research Center. Google is opening a campus in Sunnyvale in 2012. Indeed, Sunnyvale was the #1 top rated City throughout North and South America for "Best Economic Potential", according to Financial Times "American Cities of the Future 2011/12" report. Sunnyvale also topped the list of "25 Most Inventive Cities" in the nation with more patents per capita than any other as ranked by TheDailyBeast.com, a merger of the Daily Beast & Newsweek.
"Rene Schena, CEO of Arrayit Corporation (OTCBB:ARYC) demonstrates leadership, determination and the ability to project success through a business with fantastic potential," said the Sunnyvale Economic Development spokesperson. Arrayit's microarray technology is purchased by researchers and institutions around the world. Arrayit also provides OEM manufacturing in Sunnyvale for multi-billion dollar corporations. As CEO, Ms. Schena was ranked "11th Largest Woman Owned Business" in 2005 by the Silicon Valley Business Journal, and as a private company, twice achieved "Inc 500 Fastest Growing Companies in America" by Inc. Magazine. Now publicly traded, Arrayit's continuing research and development of novel microarray applications are leading the company beyond research tools and instrumentation and into the clinical diagnostics arena, starting with its OvaDx ovarian cancer diagnostic.
The video documentary produced by the City of Sunnyvale will be available mid February 2012.
About Arrayit
Arrayit Corporation leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Click here for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-KA for the fiscal year ended December 31, 2010 and Form 10-QA for the fiscal quarter ended September 30, 2011.